Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486174 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL6843570 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL1486172 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL28520254 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL67120 | 0.87 | CA1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL59435 | 0.87 | CA1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL2160514 | 0.87 | CA1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL23749797 | 0.86 | HDAC6 (0.32) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL26449279 | 0.86 | HDAC6 (0.32) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL26449223 | 0.86 | HDAC6 (0.32) | AAK1MMP13HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | AAK1 1519/4885MMP13 4411/4885TP53 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.